Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It?
10:31am, Friday, 24'th Oct 2025
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth
01:07pm, Thursday, 23'rd Oct 2025
Added 304,281 shares in AbbVie; estimated transaction value of $61.96 million Trade value was 0.23% of the fund's reportable U.S. equity assets under management Post-trade stake: 2,324,286 shares valu
AbbVie: Navigating Challenges and Seizing Opportunities in the Pharma Sector
07:00pm, Wednesday, 22'nd Oct 2025
Explore the exciting world of AbbVie (ABBV 1.17%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends a
AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know
06:45pm, Wednesday, 22'nd Oct 2025
AbbVie (ABBV) concluded the recent trading session at $228.68, signifying a -1.17% move from its prior day's close.
AbbVie Up More Than 30% in 6 Months: How to Play the Stock
11:30am, Wednesday, 22'nd Oct 2025
AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and neuroscience.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
10:00am, Wednesday, 22'nd Oct 2025
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
This 3 Stocks Portfolio Provides Monthly Income
09:01pm, Tuesday, 21'st Oct 2025
Who doesn't like payday? Investors can structure a portfolio that provides monthly income with this combination of three stocks.
Final Trades: Abbvie, Qualcomm, Aptiv, and Palo Alto Networks
02:27pm, Tuesday, 21'st Oct 2025
The Investment Committee give you their top stocks to watch for the second half.
The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients
08:00am, Tuesday, 21'st Oct 2025
Each winner will be awarded a $20,000 grant to fuel their businesses. Since the program's inception, BOTOX® Cosmetic has awarded more than $1 million in grants to The Confidence Project entrepreneurs
Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings
11:11am, Monday, 20'th Oct 2025
ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.
AbbVie's Rinvoq shows superiority over Humira in head-to-head study
08:12am, Monday, 20'th Oct 2025
AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira, meeting the main goal of a head-to-head trial.
Upadacitinib demonstrated superiority versus adalimumab for primary endpoint of achieving low disease activity (DAS28-CRP≤3.2) and ranked secondary endpoint of remission (DAS28-CRP
Medical Stocks Worth Watching – October 18th
01:40am, Monday, 20'th Oct 2025
Hims and Hers Health, Eli Lilly and Company, UnitedHealth Group, Gilead Sciences, AbbVie, Johnson and Johnson, and Thermo Fisher Scientific are the seven Medical stocks to watch today, according to Ma
AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition
04:34pm, Friday, 17'th Oct 2025
AbbVie earns a Strong Buy rating in my book, driven by Rinvoq's label expansions and robust immunology pipeline growth. ABBV achieved FDA approval for Rinvoq in giant cell arteritis and reported stron
AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
09:00am, Friday, 17'th Oct 2025
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). NOR
